Sunrise Oncology Partners
233 Spring Street
New York, NY 10013
P: (212) 123­1223
F: (212) 123­1224
Patient Nam e:  Mott, Elizabeth  
Patient Number: 12345678Date: 05/01/2018
Date Of Birth:   08/29/1960
Date Type Details Outcome Comment
5/1/2018 Other Therapies Synthroid 175 mcg tablet Active
5/1/2018 Other Therapies Zoloft 50 mg tablet Active
Allergies
No known allergies have been entered for this patient.  
Medical and Surgical History
Hypothyroidism. Mild anxiety.
Date Type ICD­9 ICD­10 Problem Comment Status
Date Type Details Outcome Comment
9/18/2018 Surgery Tonsillectomy 1960s
Social History
Patient is mar ried.  Denies history of tobacco or dr ug use.  Mrs. Mott reports the following support system : lives with family. Her diet 
consists of regular meals. S he indicates her daily activity lev el as: daily ac tivities.
Alcohol Use: Yes,  glass of wine, weekly.
Family History
Reviewed. No family history of breast cancer. Her father has a history of colon polyps.
Gyn History
Menar che at the age of 12. LMP more than 10 years ago.
Review Of  Systems
Constitutional Symptoms: Patient reports:  no fatigue,  no weakness,  no weight loss,  no fevers, no chills, no diaphoresis,  no night 
sweat s, no hot flashes,  exertional dyspnea, no cough
Eyes: Patient offers no eye complaints. 
Gastrointestinal : Patient offers no gastrointestinal com plaints. no nausea,  no vomiting, no dysphagia,  no abdominal pain,  no diarrhea,  no 
constipation
Musculoskeletal: bone pain,  no back pain,  no arthralgia 
Integumentary: Patient reports: no rash, no pruritis, no skin lesions, no dry skin
Page 1 of 2  
INITIAL CONSULTATION
Chief Complaint
Mrs. Elizabeth M ott is a very pleasant 57 y/o woman who recently felt a lump on her left breast with reddish coloration for 
which she went for evaluation to her  PCP. He immediately  ordered a mammogr am which showed an abnormal area of her 
breast at the 12:00 position. She had a biopsy of this, revealing invasive ductal carcinoma, and subsequent workup by  PET/
CT revealed metastasis to bone and liver, as well as significant adenopathy. She has been referred to us for evaluation. She 
denies any family history of breast or ovarian cancer. She is without personal history of cancer of any k ind. She reports 
history of anxiety and hypothyroidis m. Patient is her e to discus s stage IV breast cancer diagnosis and options for systemic 
therapy.
Ongoing Treatment EventsNeurological: Patient reports: no headache, no peripheral neuropathy, no foc al weakness, no tremor, no altered cons ciousness, n
oseizures, no speech impair ment, no dizziness.  no paralysis,  nervousness,
Vital Signs
Vitals on  5/1/2018  09:17:00 AM: Height=66in, Weight=155lb, Pulse=74, Systolic BP=122, DiastolicBP=68
Physical E xam
General:  Patient appear s: well developed and well nourished,  No alopecia noted. 
Eyes: No scleral icterus, and/or pallor. Conjunctiva clear. EOM s intact. Pupils  equal and reactive to light. 
Cardiovascular:  Heart with regular rate and rhythm. Normal S1 and S2. S3, S4 No gallop. No rubs or clicks. No bruits. Pedal pulses  
present. 
Chest: Clear no rales/rhonchi. No dullness to percussion. No wheezing. Chest wall expansion normal. No ches t wall tender ness. No  
stridor. 
Abdomen:  Soft. Non­tender. Non­dis tended. No palpable masses. No ascites. No hepatosplenomegaly. Bowel sounds  present in all  
quadrants. No hernia. 
Hematologic/
Lymphatic:  No cervical lymphadenopathy . No supraclavicular  lymphadenopathy. No axillar y lymphadenopathy. No inguinal  
lymphadenopathy . No petec hiae. No ecchy mosis. 
Skin: No rashes. No lesions.  Extremities appear normal. No evidence of cyanosis.  No edema.  No clubbing present. 
Neurologic:  Alert and oriented.  Normal speec h. Cranial nerves in tact. 
Genitourinary:  Examination deferred. 
Rectal: Examination deferred. 
Gynecological:  Examination deferred.
Laboratory Results
Lab r esults on 5/1/2018: Sodium=135 mmol/L, Potassium=2.9 mmol/L, CO2= 31 mmol/L, Chloride=99 mmol/L, Glucose=84 mg/dL, 
Calcium=9.0 mg/dL, BUN=14 mg/dL, Creat=1.1 mg/dL, A lk Phos=45 U/L, ALT=21 U/L, AST=23 U/L, Total Bili=0.9 mg/dL, Albumin=3.7g/
dL, Total Protein=7.5 g/dL
Imaging Results
Radiology results were reviewed and discussed with the patient, including  4/2018­ MRI Brain ­ no metastasis­ deep white matter change  
s suggestive of inflammator y process.  PET/CT -  left breast mass; diffuse bone metastases; liver les ions suspicious for metastatic breast 
cancer.
Primary Dx 
198.5 - Secondary malignant neoplasm of bone and bone m arrow, Diagnosed A pr 2018
174.9 - Malignant neoplas m of breast (female), unspec ified site, Diagnosed A pr 2018
Assessment
I have discussed with the patient the diagnosis, prognosis and natural history of metastatic breast canc er. I have discussed the incurable 
nature of the diseas e and the palliative nature of treatment. I have discussed the r ational for tr eatm ent in patients like her with stage IV , 
ER/PR positive, HER- 2/neu positive breast cancer. We have discus sed pertinent trials with regard to Her ceptin ther apy as well as 
addition of Perjeta, possible side effects and complications , and management of those. I have reviewed NCCN guidelines with the 
patient. After doing this, patient expr essed understanding and is agreeable to pur sue TH and Per jeta in s tandard doses.
Recommendation/Plan
Time spent with patient was  90 minutes. Over half the time was spent counseling and coordinating care, which included the  
following:
Arranged patient treatment education.  OV in 1 week to start therapy.
Reviewed with patient  treatment s ide effect s. 
Supportive measures  reviewed.
All questions answered.
Fax to: John Wilson, MD; Neena Sangha, M D MP H
Page 2 of 2  Electronically signed:DATE May 1, 2018  
TIME 10:46AM  
Shannon Wu, M.D.
